MedWatch

Novo Nordisk prepares to launch diabetes tablet in India

Rybelsus may be accessible for diabetes patients in India from 2022 onwards, states Novo Nordisk.

Photo: Novo Nordisk / PR

Novo Nordisk has set its sights on India's large group of diabetes patients as a future market for the treatment Rybelsus, which is the tablet-based form of the Danish pharmaceutical company's newest diabetes treatment semaglutide.

In an interview with media Financial Express, Novo Nordisk General Manager for UAE, Saudi, Qatar, Kuwait, Bahrain, Oman and Yemen Vikrant Shrotriya states that the firm plans to launch this treatment in the country in February 2022 at the latest.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs